LIBERTY Endovascular Robotic System
NDA- Indications
- Endovascular procedures
Company intelligence / Profile preview
Microbot Medical’s flagship product, the LIBERTY Robotic System, has demonstrated promising preclinical results as a single-use endovascular robotic system designed to increase access to minimally invasive procedures. The company expects FDA clearance and U.S. commercial launch in Q3 of 2025. Collaborations with Corewell Health and Emory University support ongoing development and validation efforts.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Microbot Medical.